Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00060957 · ClinicalTrials.gov registry record · Phase 2

Botulinum Toxin (BOTOX) for Cerebral Palsy

A Phase 2 study of Cerebral Palsy and Muscle Spasticity, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

Completed
Registry status
Phase 2
Development phase
40
Enrollment target
1
Study location

NCT00060957: Completed Phase 2 study of Cerebral Palsy and Muscle Spasticity, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

NCT00060957 is a Phase 2 study of Cerebral Palsy and Muscle Spasticity that has completed, run by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The registered enrollment target is 40 participants, below the 229-participant average among 91 other Cerebral Palsy trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00060957, a Phase 2 study of Cerebral Palsy and Muscle Spasticity, has completed, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

COMPLETED
Registry status
Phase 2
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

This study examines botulinum toxin (BOTOX, or BTX) for the treatment of muscle twitches and spasticity associated with cerebral palsy in children. Botulinum toxin is a naturally occurring bacterial toxin (botulinum toxin) that inactivates certain parts of muscles.

Interventions

  • DRUG Botulinum toxin type A

Study Locations (1)

Washington

  • Children's Hospital and Regional Medical Center - Seattle

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 1997-07
Phase Phase 2

What the finished NCT00060957 record still lists

NCT00060957 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 229-participant average among 91 other Cerebral Palsy trials with a reported enrollment target (83% lower).

The record links to 2 conditions, with Cerebral Palsy appearing as the primary indexed condition, and to 1 intervention - of which Botulinum toxin type A is the first listed.

NCT00060957 reports a single indexed study location in Washington.

Frequently Asked Questions

What is clinical trial NCT00060957 about?

NCT00060957 is a clinical study titled "Botulinum Toxin (BOTOX) for Cerebral Palsy". This study examines botulinum toxin (BOTOX, or BTX) for the treatment of muscle twitches and spasticity associated with cerebral palsy in children. Botulinum toxin is a naturally occurring bacterial toxin (botulinum toxin) that inactivates certain parts of muscles.

What is the current status of trial NCT00060957?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 1997-07.

What conditions does trial NCT00060957 study?

This clinical trial studies the following conditions: Cerebral Palsy, Muscle Spasticity.

What interventions are being tested in trial NCT00060957?

The interventions under investigation include: Botulinum toxin type A (DRUG).

Who is sponsoring clinical trial NCT00060957?

This trial is sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), which has 305 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00060957 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cerebral Palsy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00060957's enrollment target sits among peer trials

40 44th of 91 higher than 48 of 91 other Cerebral Palsy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cerebral Palsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00060957, the US trial registry maintained by the National Library of Medicine. NCT00060957 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.